XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Show more
Type
Private
HQ
Waltham, US
Founded
2011
Size (employees)
17 (est)-54%
Website
xtuit.com
XTuit Pharmaceuticals was founded in 2011 and is headquartered in Waltham, US
Report incorrect company information

XTuit Pharmaceuticals Office Locations

XTuit Pharmaceuticals has an office in Waltham
Waltham, US (HQ)
35 Gatehouse Dr
Show all (1)
Report incorrect company information

XTuit Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2011

Total Funding

$26 m

Latest funding size

$22 m

Time since last funding

3 years ago

Investors

XTuit Pharmaceuticals's latest funding round in June 2015 was reported to be $22 m. In total, XTuit Pharmaceuticals has raised $26 m
Show all financial metrics
Report incorrect company information